Business
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint. On track to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026. Ended the first quarter 2026 w
About this update from Ethos Technologies Inc.
[{"type":"image","alt":"aTyr Pharma, Inc.","displaySize":"","headline":null,"caption":"aTyr Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/9b5f13b39204584ce149705b65740791"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MoNUfK7zbCyPIWUInQpxrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MQ--/https://media.zenfs.com/en/globenewswire.com/9b5f13b39204584ce149705b65740791","width":300,"height":179},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MoNUfK7zbCyPIWUInQpxrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MQ--/https://media.zenfs.com/en/globenewswire.com/9b5f13b39204584ce149705b65740791","width":300,"height":179}},"lazy":false},{"type":"text","content":" Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA.","length":110,"tagName":"p"},{"type":"text","content":"Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint. ","length":242,"tagName":"p"},{"type":"text","content":"On track to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026.","length":115,"tagName":"p"},{"type":"text","content":"Ended the first quarter 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments.","length":107,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2026 results and provided a corporate update.","length":334,"tagName":"p"},{"type":"text","content":"“2026 is off to a productive start, as we now have a clear path forward for efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), following our recent Type C meeting with the U.S. Food and Drug Administration (FDA),” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Based on feedback from the FDA, we plan to file an investigational new drug (IND) application next ...